PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
30 mai 2024 07h00 HE
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
29 mai 2024 07h00 HE
|
PMV Pharmaceuticals, Inc.
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation...
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
09 mai 2024 08h00 HE
|
PMV Pharmaceuticals, Inc.
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors ...
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
27 mars 2024 08h00 HE
|
PMV Pharmaceuticals, Inc.
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2...
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
18 mars 2024 16h01 HE
|
PMV Pharmaceuticals, Inc.
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation...
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
29 févr. 2024 16h01 HE
|
PMV Pharmaceuticals, Inc.
Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors...
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
26 févr. 2024 08h00 HE
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
18 janv. 2024 16h01 HE
|
PMV Pharmaceuticals, Inc.
Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling...
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
05 janv. 2024 16h01 HE
|
PMV Pharmaceuticals, Inc.
PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs)Michael...
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
09 nov. 2023 08h00 HE
|
PMV Pharmaceuticals, Inc.
Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across...